Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has
successfully completed patient enrollment in the first of two pivotal
phase 3 trials evaluating the safety and efficacy of two plecanatide
doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation
The randomized, 12-week, double-blind, placebo-controlled pivotal phase
3 CIC trial is evaluating plecanatide 3.0 and 6.0 mg, once-daily oral
tablets, in approximately 1350 adult patients with CIC.
for Synergy Pharmaceuticals Completes Patient Enrollment for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks